Silexion Therapeutics Corp (SLXN) Stock Price, Quote & News

Company Profile

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatmen...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 2 674 3430

Fax: 972 2 643 0982

Website: silexion.com

Address:

The Goldyne Savad Inst. of Gene Therapy, Hadassah Hebrew Univ Medical Ctr, Jerusalem, Israel

WallStWireAds Jan. 13 at 3:16 PM

$SLXN https://alphacatalyst.beehiiv.com/p/this-microcap-biotech-is-entering-human-trials-with-a-new-approach-to-cancer-s-undruggable-target-na

0 · Reply

Sookie1962 Jan. 8 at 6:28 PM

$SLXN

0 · Reply

Sookie1962 Jan. 8 at 6:27 PM

$SLXN

0 · Reply

JohnTrack Jan. 6 at 4:20 PM

$SLXN eyes peeled, nothing forced...

0 · Reply

DARKP00L Jan. 6 at 12:50 PM

$SLXN 07:36 on Jan. 06 2026 Silexion Targets Human Trials in 2026 After Strong Progress Against KRAS Cancers #tradeideas

0 · Reply

JohnTrack Jan. 6 at 12:49 PM

$SLXN headline just crossed!! https://www.rapidticker.com/news/slxn--silexion-therapeutics-releases-ceo-7015be

0 · Reply

WallStWireAds Jan. 6 at 12:31 PM

$SLXN https://caplynx.io/9neSc62

0 · Reply

Sookie1962 Jan. 3 at 7:22 PM

$SLXN i have Question it seem like someone is again buying alot like really alot of warrants of SLXNW i wonder is there something going here???!!

0 · Reply

2pumps1dump Dec. 31 at 11:24 AM

$SLXN why the drop? 🧐

0 · Reply

Sam_hs Dec. 30 at 4:53 PM

$SLXN I need translation for the 2 comments below me lol

1 · Reply

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

Nov 26, 2025, 7:30 AM EST - 7 weeks ago

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Nov 25, 2025, 9:15 AM EST - 7 weeks ago

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Nov 12, 2025, 9:00 AM EST - 2 months ago

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Sep 30, 2025, 8:40 AM EDT - 3 months ago

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Sep 25, 2025, 8:45 AM EDT - 3 months ago

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

Sep 11, 2025, 1:26 PM EDT - 4 months ago

Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data

Sep 11, 2025, 9:17 AM EDT - 4 months ago

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Sep 11, 2025, 7:00 AM EDT - 4 months ago

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Sep 4, 2025, 9:25 AM EDT - 4 months ago

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Sep 2, 2025, 8:45 AM EDT - 4 months ago

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Aug 12, 2025, 8:00 AM EDT - 5 months ago

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 PM EDT - 5 months ago

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Jul 31, 2025, 9:55 AM EDT - 5 months ago

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Jul 16, 2025, 8:44 AM EDT - 6 months ago

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Jul 9, 2025, 8:30 AM EDT - 6 months ago

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

May 22, 2025, 3:46 PM EDT - 8 months ago

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 21, 2025, 8:45 AM EDT - 8 months ago

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

May 13, 2025, 4:45 PM EDT - 8 months ago

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 23, 2025, 9:20 AM EDT - 9 months ago

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Mar 28, 2025, 8:30 AM EDT - 10 months ago

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Mar 21, 2025, 8:30 AM EDT - 10 months ago

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Mar 18, 2025, 4:29 PM EDT - 10 months ago

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Mar 17, 2025, 8:15 AM EDT - 10 months ago

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Mar 5, 2025, 12:05 PM EST - 11 months ago

Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

Mar 5, 2025, 8:30 AM EST - 11 months ago

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Mar 3, 2025, 8:30 AM EST - 11 months ago

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Feb 25, 2025, 8:30 AM EST - 11 months ago

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Jan 29, 2025, 5:30 PM EST - 1 year ago

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Jan 29, 2025, 9:59 AM EST - 1 year ago

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Jan 28, 2025, 8:29 AM EST - 1 year ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Jan 16, 2025, 12:08 PM EST - 1 year ago

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

Jan 16, 2025, 11:04 AM EST - 1 year ago

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Jan 16, 2025, 8:51 AM EST - 1 year ago

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

LUV

Jan 15, 2025, 8:00 PM EST - 1 year ago

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Jan 15, 2025, 4:01 PM EST - 1 year ago

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Jan 13, 2025, 7:50 AM EST - 1 year ago

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Dec 17, 2024, 9:36 AM EST - 1 year ago

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

AMGN

Nov 22, 2024, 4:30 PM EST - 1 year ago

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Nov 20, 2024, 8:30 AM EST - 1 year ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Oct 1, 2024, 6:45 AM EDT - 1 year ago

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Sep 24, 2024, 9:25 AM EDT - 1 year ago

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

Sep 9, 2024, 7:32 AM EDT - 1 year ago

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

WallStWireAds Jan. 13 at 3:16 PM

$SLXN https://alphacatalyst.beehiiv.com/p/this-microcap-biotech-is-entering-human-trials-with-a-new-approach-to-cancer-s-undruggable-target-na

0 · Reply

Sookie1962 Jan. 8 at 6:28 PM

$SLXN

0 · Reply

Sookie1962 Jan. 8 at 6:27 PM

$SLXN

0 · Reply

JohnTrack Jan. 6 at 4:20 PM

$SLXN eyes peeled, nothing forced...

0 · Reply

DARKP00L Jan. 6 at 12:50 PM

$SLXN 07:36 on Jan. 06 2026 Silexion Targets Human Trials in 2026 After Strong Progress Against KRAS Cancers #tradeideas

0 · Reply

JohnTrack Jan. 6 at 12:49 PM

$SLXN headline just crossed!! https://www.rapidticker.com/news/slxn--silexion-therapeutics-releases-ceo-7015be

0 · Reply

WallStWireAds Jan. 6 at 12:31 PM

$SLXN https://caplynx.io/9neSc62

0 · Reply

Sookie1962 Jan. 3 at 7:22 PM

$SLXN i have Question it seem like someone is again buying alot like really alot of warrants of SLXNW i wonder is there something going here???!!

0 · Reply

2pumps1dump Dec. 31 at 11:24 AM

$SLXN why the drop? 🧐

0 · Reply

Sam_hs Dec. 30 at 4:53 PM

$SLXN I need translation for the 2 comments below me lol

1 · Reply

MonumentMend Dec. 26 at 5:16 PM

$SLXN Expectations are recalibrating toward pragmatic delivery instead of lofty projections. Balance sheet resilience remains an underappreciated swing factor. Demonstrated durability would lengthen investor time horizons. The forward path ultimately depends on disciplined delivery.

0 · Reply

GaussianGains Dec. 24 at 12:18 PM

$SLXN Forward visibility remains uneven as strategic priorities translate into measurable operating outcomes. Execution slippage remains the dominant downside risk.

0 · Reply

JTTrader Dec. 22 at 7:03 PM

$SLXN Who's been buying all those warrants again?

3 · Reply

PulseTraderZ Dec. 17 at 12:01 PM

$SLXN thin biotech, binary catalyst setup where range is just storing energy for the next data release

0 · Reply

Warrenbuffet13 Dec. 17 at 9:30 AM

$SLXN is up !!!! +30% let’s bring it to 10 dollars !!!

0 · Reply

2pumps1dump Dec. 16 at 1:52 PM

$SLXN 👀 has news 🗞️

0 · Reply

JohnTrack Dec. 16 at 1:46 PM

$SLXN story flash... https://www.rapidticker.com/news/slxn-silexion-therapeutics-announces-submission-of-75713c

0 · Reply

WallStWireAds Dec. 16 at 1:42 PM

$SLXN https://caplynx.io/3gSfOZk

0 · Reply

Stock_Catcher Dec. 16 at 1:40 PM

$SLXN Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

0 · Reply

JarvisFlow Dec. 15 at 2:45 PM

Litchfield Hills has updated their rating for Silexion Therapeutics ( $SLXN ) to Buy with a price target of 6.

0 · Reply

quodo Dec. 15 at 2:21 PM

$SOXD.TSX $TERG $THCH $SLXN Leverage ETFs and turnarounds move fast… until they don’t. $CAPS is building a durable platform with recurring revenue and disciplined M&A. That’s how you get rerated.

0 · Reply

WallStWireAds Dec. 15 at 1:36 PM

$SLXN https://www.benzinga.com/content/49390499/silexion-therapeutics-receives-6-price-target-and-buy-rating-from-litchfield-hills-research-nasdaq-s

0 · Reply

Market Cap	6.63M
Revenue (ttm)	0.00
Net Income (ttm)	-16.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.22

Volume	10,942
Avg Vol	57,894
Day's Range	N/A - N/A
Shares Out	3.13M
Stochastic %K	61%
Beta	-0.03
Analysts	Strong Sell
Price Target	$9.00